NRx Pharmaceuticals, Inc. (NRXP)
- Previous Close
2.0300 - Open
2.0200 - Bid 1.4400 x 200
- Ask 2.5400 x 200
- Day's Range
1.9600 - 2.0200 - 52 Week Range
1.1000 - 6.0100 - Volume
48,283 - Avg. Volume
182,605 - Market Cap (intraday)
34.105M - Beta (5Y Monthly) 1.45
- PE Ratio (TTM)
-- - EPS (TTM)
-2.3600 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
28.50
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
www.nrxpharma.comRecent News: NRXP
View More
Performance Overview: NRXP
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NRXP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NRXP
View MoreValuation Measures
Market Cap
34.34M
Enterprise Value
39.47M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-224.60%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-25.13M
Diluted EPS (ttm)
-2.3600
Balance Sheet and Cash Flow
Total Cash (mrq)
1.44M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
126.25k